|Report Code: PP10105||Report Type: Indication Pipeline Reports||Available format:|
Major depressive disorder, also known as the clinical depression, is characterized by a constant sense of despair and hopelessness. It usually affects daily activities such as study, sleep, and eating. Common symptoms observed in major depressive disorder are fatigue, indecisiveness, impaired concentration, feelings of worthlessness or guilt, insomnia or hypersomnia, restlessness, significant weight loss or gain and recurring thoughts of death or suicide. According to the National Institute of Mental Health, an estimated 16.1 million adults aged 18 or older in the U.S. had at least one major depressive episode in 2014.
VistaGen Therapeutics Inc. is developing AV-101, a new generation oral antidepressant, for the treatment of major depressive disorder. NeurOp Inc., and ACADIA Pharmaceuticals Inc. are some other key players involved in the development of drugs for the treatment of major depressive disorder.